Immuno-oncology is a way to treat cancer by using the body’s immune system. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that binds a patient’s own T cells to cancer cells. Because BiTE technology is flexible, it is easy to make molecules that attack tumor-specific antigens, which makes immuno-oncotherapy possible. Blinatumomab was the first standard BiTE molecule to be approved. It targets CD19 surface antigens on B cells and is mostly unaffected by genetic changes or escape mechanisms inside cells. More BiTE molecules are being made to treat other blood cancers (like multiple myeloma, acute myeloid leukaemia, and B-cell ne-Hodžkina limfoma) and solid tumours (like prostate cancer, glioblastoma, stomach cancer, and small-cell lung cancer). BiTE molecules that have a longer half-life than the standard ones are also being made. With BiTE technology, advances in immuno-oncology could make it easier to treat both blood and solid tumours and make them more effective when used with other treatments.
Kas ir BiTe terapija?
Immuno-oncology therapies are scientifically proven ways to treat different types of solid and asins vēzis. Hematologic cancers are a good fit for treatments that target the immune system because cancerous blood cells move around with immune cells. Several imūnterapiju tiek izstrādāta vēža ārstēšana.
Monoclonal antibody checkpoint inhibitors that stop the binding of checkpoint proteins (like PD-1 and CTLA-4) are useful against many types of cancer. They work well and are safe for many solid tumours, especially when they target PD-1. Non-small-cell lung, kidney, and bladder cancers have all been treated successfully with these drugs. But many people don’t react to checkpoint inhibitors or get sick again after taking them. Except for non-Hodgkin limfoma, most results on hematologic cancers have been disappointing, especially for myeloma and leukaemia, where the overall response rate in approved indications ranges from 12.0% to 48.5%.8-15.
Other immuno-oncology treatments, on the other hand, have a higher success rate. Chimeric antigen-receptor (CAR) T-cell therapies change a patient’s T cells to attack a specific cellular antigen, such as CD19 in the treatment of B-cell malignancies and B-cell maturation antigen (BCMA) in the treatment of multiplā mieloma (MM). CAR T-cell treatments have shown promise in treating hematologic cancers. They haven’t been as effective in treating solid tumours, but there have been some good results with neiroblastoma, human epidermal growth factor receptor tumours, and non-small-cell lung cancer. The genetic modification and in vitro multiplication of T cells take a long and complicated manufacturing process. This is a downside of this therapy because it makes it harder for patients to get this treatment quickly and in large numbers. The fact that lymphodepletion through chemotherapy preparation must be done first as a requirement for improved effectiveness is also a drawback.
BiTE (bispecifiskā T-šūnu piesaistītāja) terapija saista pacienta paša T šūnas ar audzēja ekspresētajiem antigēniem. Tas ieslēdz pacienta paša T šūnu citotoksisko spēju nogalināt vēzi, nemainot T šūnu gēnus vai nepieprasot tos audzēt vai manipulēt ārpus ķermeņa. BiTE molekulas var izmantot vienas pašas kā zāles vai kopā ar citām ārstēšanas metodēm, lai padarītu tās efektīvākas.
BiTe darbības mehānisms
BiTE molecules are antibody constructs with two binding domains. One recognises tumor-expressed antigens (such as BCMA, CD19, or -like protein [DLL3]), and the other, CD3, recognises T cells (Fig. 1). Two single-chain variable fragment (scFv) regions from monoclonal antibodies are connected by a flexible peptide linker to make the binding domains. The first scFv binding region can be changed to target any surface antigen, so it can be used right away to treat a wide range of tumours and can be used again later. The second scFv binding region always binds to CD3, which is a part of the T-cell receptor complex that never changes. When a BiTE molecule interacts with both a cytotoxic T cell and a tumour cell, the T cells begin to multiply. This increases the amount of effector cells and makes BiTE therapy more effective. Then, the death of cancer cells is started. BiTE molecules can get any T cells to do this because they don’t need co-stimulation or the usual processes of the major histocompatibility complex.
Blinatumomab is the first and only BiTE therapy that has been approved. It targets the CD19 receptor on both normal and cancerous B cells. It is a highly potent molecule with cytotoxic effects seen at low exposures (10–100 pg/mL)26. In its presence, T cells can perform serial-target lysis, quickly binding to and killing many cells. This is how BiTE therapies work, and it can be seen in other BiTE molecules that are still in research. In akūta limfoblastiskā leikēmija (ALL), blinatumomab has been shown to be effective and safe. In 2014, the US Food and Drug Administration gave it fast approval, and in 2017, it got full approval for relapsed or refractory (R/R) B-cell precursor (BCP) ALL. In 2018, accelerated approval was given to blinatumomabs for treating BCP-ALL with minimum residual disease (MRD). This was the first approval for this use. In November 2015, the European Medicines Agency also gave it a green light for BCP-ALL with a Philadelphia chromosome (Ph) that is negative and R/R. Blinatumomab is approved for R/R BCP-ALL in adults and children in 57 countries, including Japan, all countries in the European Union, Canada, and Australia.
Blinatumomabs pacientu ar BCP-ALL ārstēšanai
Blinatumomabs ir mainījis BCP-ALL ārstēšanas veidu. Salīdzinot ar standarta aprūpes (SOC) ķīmijterapiju, tā ir palielinājusi kopējo dzīvildzi (OS) un samazinājusi noteiktu blakusparādību (AE) skaitu. Vairāki nozīmīgi pētījumi, tostarp randomizēti kontrolēti pētījumi, parādīja, ka blinatumomabs ir drošs un iedarbojas uz BCP-ALL gan pieaugušajiem, gan bērniem. CAR T-šūnu terapija, ir tikai dati no 2 vienas grupas pētījumiem (clinicaltrials.gov ID NCT01626495 un NCT01029366), kuros tika ārstēti 25 bērni (vecumā no 5 līdz 22 gadiem) un 5 pieaugušie (vecumā no 26 līdz 60 gadiem) ar R/R BCP-ALL un T-cell ALL. Taču rezultāti ir daudzsološi (pilnīga atbildes reakcija [CR] 90%, ilgstoša remisija ar 6 mēnešu dzīvildzi bez notikumiem 67% un kopējā dzīvildze [OS] 78% [vidējā novērošana, 7 mēneši; diapazons, 1–24 mēneši]).
Pētījums TOWER (3. fāze, randomizēts, atklāts pētījums, kurā tiek pētīta BiTE antivielas Blinatumomaba efektivitāte salīdzinājumā ar standarta ķīmijterapijas ārstēšanu pieaugušajiem ar recidivējošu/refraktāru B-prekursoru ALL; klīniskās izpētes.gov identifikators NCT02013167) salīdzināja prethemoterapijas monoterapijas efektus pret hemaocvilnibli. ārstēti pieaugušie ar Ph-negatīvu, R/R BCP-ALL. Tā kā cilvēki dzīvoja ilgāk, pētījums tika agri pārtraukts. Blinatumomaba grupā bija tādas pašas blakusparādības kā iepriekšējos pētījumos, un blinatumomabam bija zemāki iedarbībai pielāgoti AE rādītāji nekā SOC.34 Blinatumomabs darbojas arī cilvēkiem ar Ph-pozitīvu, R/R BCP-ALL un bērniem ar Ph-negatīvu, R/R BCP-ALL.
30% to 50% of people with BCP-ALL in complete hematologic remission show persistent MRD. In the single-arm, phase 2 BLAST study (A Confirmatory Multicenter, Single-Arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients With MRD of B-Precursor Acute Lymphoblastic Leukaemia; clinicaltrials.gov identifier NCT01207388), blinatumomab was tested on patients with BCP-ALL in first or later complete After blinatumomab treatment, 78% of patients who were MRD positive became MRD negative. The 5-year OS study showed a median OS of 36.5 months, and more than half of those who had a complete MRD response after the first cycle of blinatumomab were still alive at 5 years, which suggests that the treatment might be able to cure some patients. AEs were seen that were linked to citokīnu atbrīvošanās sindroms (CRS).31 Other studies, like NCT03023878 and NCT03340766, are still looking at blinatumomab in first-line settings and in combination with other treatments.
CD19-targeted treatments have been linked to failure because of the loss of CD19 antigen after treatment. The failure rates for blinatumomab range from 8% to 35%, and for CAR T-šūnu terapija, they range from 39% to 65%.36-40 We don’t fully understand what causes therapy to fail, but one possibility is immunoediting, in which antigen loss is caused by a T-cell-dependent process called immunoselection, which lets tumour cells get away.41 Lineage switch and epitope loss under therapy pressure have also been suggested as ways for tumours to escape treatment. However, a recent study on epitope loss found that some CD19 isoforms that help CAR T-cells escape were already present at the time of diagnosis. This suggests that combining treatments might be helpful. Another thing that can cause immunotherapy to fail is called “inhibitory T-cell signalling.” In this case, the blocking programmed death ligand-1 (PD-L1) is interesting because it is more common in B-cell ALL cells from patients who don’t respond to blinatumomab and can make CD3 BiTE molecules less effective.43 By making a CD28/PD-L1 BiTE that triggers the CD28 co-stimulatory signal instead of the inhibitory signaling pathway that is usually seen when a T cell binds to a PD-L1-expressing cancer cell, this inhibition could be turned off.43 Dual-targeted CAR T cells are also being looked into as a way to make up for the loss of tumour antigens. This can be done by modifying each T cell with 2 CAR molecules and 2 different binding domains (dual-signaling CAR) or by putting 2 different binding domains on 1 CAR molecule at the same time (TanCAR).
Nevēlamie notikumi ar BiTE un tās vadību
Blinatumomaba klīniskajos pētījumos visizplatītākās blakusparādības ir drudzis, zems balto asinsķermenīšu skaits un zems trombocītu skaits. Daži no svarīgākajiem riskiem ir DRS, neirotoksicitāte un zāļu kļūdas. Neirotoksicitāte var rasties arī ar CD19 specifisku CAR T-šūnu ārstēšanu, taču tas var nebūt CD19 dēļ. 1./1.b fāzes pētījuma rezultāti, kas joprojām turpinās par CD20/CD3 mērķiem, parādīja, ka 3. vai augstākas pakāpes CNS AE bija reti (3% no visiem 3. pakāpes AE). Lielāko daļu laika blinatumomaba reakcija uz CRS ir viegla, bet retos gadījumos tā var būt smaga un pat dzīvībai bīstama. Iekaisuma reakcijas var mazināt ar kortikosteroīdiem. Lai samazinātu CRS iespējamību, vislabāk ir ievadīt prednizona vai deksametazona infūziju pirms pirmās blinatumomaba devas un lēnām palielināt devu. Šī kortikosteroīdu lietošana pirms citām BiTE molekulām ir devusi iemeslu izmantot deksametazonu kā premedikāciju, lietojot citas BiTE molekulas. Tomēr nav skaidrs, vai šo efektu var attiecināt uz visu BiTE platformu, un tiek meklēti citi veidi, kā tikt galā ar DRS. Interleikīns 6 ir citokīns, kas izraisa DRS un ir augsts cilvēkiem, kuriem tā ir. Tocilizumabs, kas bloķē interleikīna-6 receptorus, tika izmantots CRS ārstēšanai, kas ir ļoti slikta pēc CAR T-šūnu ārstēšanas.49 Slimnīcā CRS ārstēšanai tika izmantoti arī audzēja nekrozes faktora inhibitori.
